First Tracks Biotherapeutics (HAM:B43) EPS without NRI: € (TTM As of Dec. 2024)


HAM:B43 First Tracks Biotherapeutics Inc HAM:B43
20 GF Score
Price €32.00
! 3 Warning Signs
View Full Analysis

What is First Tracks Biotherapeutics EPS without NRI?

First Tracks Biotherapeutics HAM:B43 +29.29% 20 EPS without NRI is € as of Dec. 2024. GuruFocus rates HAM:B43 with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 1,168 Biotechnology companies, First Tracks Biotherapeutics ranks worse than 85616.35% on this metric.

First Tracks Biotherapeutics's earnings per share without non-recurring items for the six months ended in Dec. 2024 was €-4.50.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for First Tracks Biotherapeutics's EPS without NRI or its related term are showing as below:

HAM:B43's 3-Year EPS without NRI Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 16.4
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

First Tracks Biotherapeutics's EPS (Diluted) for the six months ended in Dec. 2024 was €-4.50.

First Tracks Biotherapeutics's EPS (Basic) for the six months ended in Dec. 2024 was €-4.50.


First Tracks Biotherapeutics  (HAM:B43) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


First Tracks Biotherapeutics EPS without NRI Related Terms


First Tracks Biotherapeutics EPS without NRI Historical Data

* Premium members only.

The historical data trend for First Tracks Biotherapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

First Tracks Biotherapeutics EPS without NRI Chart

First Tracks Biotherapeutics Annual Data
Trend Dec23 Dec24
EPS without NRI
-2.80 -4.50

First Tracks Biotherapeutics Semi-Annual Data
Dec23 Dec24
EPS without NRI -2.80 -4.50

HAM:B43 vs ALT, RGNX, MDXG: EPS without NRI Comparison

For the Biotechnology subindustry, First Tracks Biotherapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


First Tracks Biotherapeutics PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, First Tracks Biotherapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where First Tracks Biotherapeutics's PE Ratio without NRI falls into.


HAM:B43
20GF Score
First Tracks Biotherapeutics Inc HAM:B43
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

First Tracks Biotherapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

For stock reported annually, GuruFocus uses latest annual data as the TTM data. EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 was €

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of € mean?
First Tracks Biotherapeutics (HAM:B43) has a EPS without NRI of € as of Dec. 2024. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on First Tracks Biotherapeutics and its competitors. According to the industry distribution chart, First Tracks Biotherapeutics ranks #999999 out of 1168 companies in the Biotechnology industry.
Is First Tracks Biotherapeutics' EPS without NRI too high?
First Tracks Biotherapeutics' current EPS without NRI is €. Based on the distribution chart, First Tracks Biotherapeutics ranks #999999 out of 1168 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, First Tracks Biotherapeutics has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does First Tracks Biotherapeutics' EPS without NRI compare to ALT and RGNX?
According to the Biotechnology industry distribution chart, First Tracks Biotherapeutics ranks #999999 out of 1168 companies for EPS without NRI. This places First Tracks Biotherapeutics in the lower half of its industry. The industry median EPS without NRI is 16.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.40, based on 1,168 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on First Tracks Biotherapeutics and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. First Tracks Biotherapeutics's current EPS without NRI is €. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is First Tracks Biotherapeutics stock overvalued right now?
First Tracks Biotherapeutics (HAM:B43) has a current EPS without NRI of €. The current EPS without NRI is €. First Tracks Biotherapeutics' overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For First Tracks Biotherapeutics (HAM:B43), the current EPS without NRI is € as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

First Tracks Biotherapeutics Business Description

Other Exchanges TRAX:USA
Address 10770 Wateridge Circle, Suite 210, San Diego, CA, USA, 92121
First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
20GF Score

Get the complete analysis for HAM:B43

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€32.00
Price